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The H3K9me3 repressive histone conformation of
p53 target promoters is abrogated in response to
p53 activation by MDM2-mediated SUV39H1 degra-
dation. Here, we present evidence that the USP7
deubiquitinase protects SUV39H1 fromMDM2-medi-
ated ubiquitination in the absence of p53 stimulus.
USP7 occupies p53 target promoters in unstressed
conditions, a process that is abrogatedwith p53 acti-
vation associated with loss of the H3K9me3 mark on
these same promoters. Mechanistically, USP7 forms
a trimeric complex with MDM2 and SUV39H1, inde-
pendent of DNA, and modulates MDM2-dependent
SUV39H1 ubiquitination. Furthermore, we show that
this protective function of USP7 on SUV39H1 is inde-
pendent of p53. Finally, USP7 blocking cooperates
with p53 in inducing apoptosis by enhancing p53
promoter occupancy and dependent transactivation
of target genes. These results uncover a layer of the
p53 transcriptional program mediated by USP7,
which restrains relaxation of local chromatin confor-
mation at p53 target promoters.
INTRODUCTION
TP53 is a well-established tumor suppressor and cellular gate-
keeper of genome stability (Bieging et al., 2014; Khoo et al.,
2014). In response to homeostatic stresses, p53 is stabilized
and recruits core transcriptional machinery proteins to its target
promoters, enabling transactivation of these genes, with cellular
outcomes including cell-cycle arrest and apoptosis (Kruiswijk
et al., 2015; Mandinova and Lee, 2011; Vousden and Prives,
2009; Zilfou and Lowe, 2009).
Chromatin conformation plays a major role in p53-depen-
dent transcription (Allen et al., 2014; Beckerman and Prives,
2010; Botcheva, 2014; Su et al., 2015). p53 interacts with
several cofactors, which have intrinsic histone-modifying
activities (Liu et al., 1999; Vaziri et al., 2001), and with histone2528 Cell Reports 14, 2528–2537, March 22, 2016 ª2016 The Authordeacetylase complexes that act specifically to remodel chro-
matin (Brooks and Gu, 2011; Dai and Gu, 2010). We and
others have shown that p53 target promoters are enriched
with the H3K9me3 (histone H3 lysine9 trimethylation) mark
and that p53 activation abrogates this repressive chromatin
conformation through MDM2 proto-oncogene (MDM2)-medi-
ated degradation of suppressor of variegation 3-9 homolog 1
(Drosophila) (SUV39H1) (KMT1A), a major methyltransferase
responsible for writing this mark (Bosch-Presegue´ et al.,
2011; Choi et al., 2012; Mungamuri et al., 2012; Zheng et al.,
2014). Further, lysine 87 of SUV39H1 has been identified as
the primary site of MDM2-mediated ubiquitination (Bosch-
Presegue´ et al., 2011).
In the absence of genotoxic stress, p53 is known to occupy
target promoters such as p21, Gadd45a, and PUMA but re-
mains transcriptionally inactive (Allen et al., 2014; Espinosa
et al., 2003; Jackson and Pereira-Smith, 2006; Kaeser and
Iggo, 2002). Specifically, MDM2 has been proposed to repress
p53 activity when co-occupied on these promoters, with p53
stress stimuli relieving such repression (Kruse and Gu, 2009;
Minsky and Oren, 2004). There is also evidence that degrada-
tion of SUV39H1, also present on these same promoters, is
required for p53-dependent transcription (Choi et al., 2012;
Mungamuri et al., 2012). However, the mechanisms respon-
sible for protecting SUV39H1 from MDM2-mediated degra-
dation and preserving the repressive H3K9me3 mark in the
absence of stress-induced p53 stabilization remain to be
elucidated.
USP7 (ubiquitin-specific peptidase 7) is known to have a dual
role in the p53-MDM2 pathway, as it deubiquitinates both p53
andMDM2. USP7 overexpression counteractsMDM2-mediated
p53 ubiquitination, which stabilizes p53, leading to apoptosis
(Li et al., 2004; Li et al., 2002). Disruption of the USP7 gene is
also lethal to p53 wild-type (WT) cells, as loss of USP7 expres-
sion enhances the auto-ubiquitination of MDM2 leading to its
degradation, resulting in p53 stabilization and apoptosis (Cum-
mins et al., 2004; Cummins and Vogelstein, 2004). The present
studies define a role of USP7 in the regulation of MDM2-medi-
ated SUV39H1 degradation and maintenance of the H3K9me3
repressive chromatin conformation on p53 target promoters in
unstressed cells.s
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Figure 1. USP7 Enhances SUV39H1 Protein Stability Independent of p53
(A and B) Western blot analysis of HCT116 p53 WT (A) and HCT116 p53/ (B) cells stably transduced with doxycycline-inducible shGFP or shUSP7 (two
sequences) and cultured in the presence of doxycycline for 48 hr.
(C) Western blot analysis of H1299 cells transiently overexpressing 1, 2, or 4 mg FLAG-USP7 for 24 hr. The amounts of proteins expressed (arbitrary units) are
shown as a line diagram.
(D) Western blot analysis of HCT116 p53/ cells transiently overexpressing FLAG-USP7 and treated with cycloheximide for indicated time points. The amounts
of proteins expressed (arbitrary units) are shown as a line diagram.
See also Figures S1 and S2.RESULTS
USP7 Enhances SUV39H1 Stability Independent of p53
To investigate whether USP7 modulates SUV39H1 expression
levels, we generated HCT116 p53 WT cells stably expressingCelldoxycycline-inducible USP7 small hairpin RNA (shRNA). The
addition of doxycycline to the culture medium reduced USP7
expression as measured at both the mRNA (Figure S1A) and
protein (Figure 1A) levels, and as expected, USP7 silencing sta-
bilized p53, resulting in induction of its target genes (Figures 1AReports 14, 2528–2537, March 22, 2016 ª2016 The Authors 2529
and S1A). We showed previously that p53 regulates SUV39H1 at
the mRNA level through p21 and at the protein level through
MDM2 (Mungamuri et al., 2012). Consistent with these data,
we observed a decrease in SUV39H1 mRNA and protein levels
under these conditions (Figures 1A and S1A), which also corre-
lated with loss of the H3K9me3 histone mark (Figure 1A).
As a control, we generated similar stables in isogenic HCT116
p53/ cells and analyzed the effect of USP7 silencing on
SUV39H1 levels. USP7 knockdown in these cells had no effect
on either the induction of p21 or downregulation of SUV39H1
mRNA levels (Figure S1B), but it resulted in reduction both of
SUV39H1 protein expression and H3K9me3 mark levels (Fig-
ure 1B). Further, downregulation of SUV39H1 protein expression
in response to USP7 silencing was inhibited when cells were
treated with the proteasomal inhibitor MG-132 (Figure S1C). All
of these findings indicated that USP7 loss destabilizes the
SUV39H1 protein independent of p53.
To further investigate the role of USP7 in regulating SUV39H1
protein stability, we exogenously overexpressed USP7 in p53
null H1299 cells and observed a USP7 dose-dependent increase
in SUV39H1 protein levels (Figure 1C). These results further
substantiated that USP7 modulates steady-state SUV39H1
levels independent of p53. Finally, we transiently overexpressed
USP7 in HCT116 p53/ cells, treated with cycloheximide to
block new protein synthesis, and observed a significant increase
in SUV39H1 half-life (Figure 1D), confirming that USP7 positively
regulates SUV39H1 protein stability.
USP7 Protects SUV39H1 from MDM2-Mediated
Degradation
MDM2 ubiquitinates SUV39H1 and targets it for proteasomal
degradation (Bosch-Presegue´ et al., 2011; Mungamuri et al.,
2012). Thus, we tested whether USP7 protects SUV39H1 from
MDM2-mediated degradation. Transient transfection of H1299
or HCT116 p53/ cells revealed that exogenous MDM2 expres-
sion led to downregulation of exogenous SUV39H1 protein
levels (Figures 2A and S2A), while USP7 co-transfection rescued
SUV39H1 expression in a dose-dependent manner (Figure 2A).
Exogenous MDM2 expression in HCT116 p53/ cells downre-
gulated levels of exogenously expressed SUV39H1 WT, but
not an MDM2-resistant SUV39H1-K87A mutant, confirming
previous findings (Bosch-Presegue´ et al., 2011) that lysine 87
is the site of ubiquitination by MDM2 (Figure S2A). Finally, doxy-
cycline-induced shUSP7 expression in HCT116 p53/ cells re-
sulted in downregulation of exogenously expressed SUV39H1
WT, but not SUV39H1-K87A, protein levels (Figure S2A). These
results support the conclusion that endogenous USP7 protects
SUV39H1 from endogenous MDM2-mediated degradation.
USP7 activity can also be inhibited at sub-micromolar concen-
trations by HBX41108, a cyano-indenopyrazine derivative (Col-
land et al., 2009). In MDM2 non-silenced p53-null H1299 cells,
USP7 inhibition using HBX41108 resulted in reduced levels of
SUV39H1WT, but not SUV39H1 K87A (site of MDM2 ubiquitina-
tion) (Figure S2B). When the same cells were pre-silenced for
MDM2, HBX41108 treatment did not result in a decrease in either
SUV39H1 WT or SUV39H1 K87A protein levels (Figure S2B).
These results indicate that MDM2 is the E3 ligase for SUV39H1
(ubiquitinating at K87 residue) and that USP7 acts to stabilize2530 Cell Reports 14, 2528–2537, March 22, 2016 ª2016 The AuthorSUV39H1 only in the presence of basal levels of MDM2.
Furthermore, a USP7 catalytically inactive mutant (C223S), as
well as the WT protein’s N-terminal domain (NTD) or C-terminal
domain (CTD), were unable to protect SUV39H1 from MDM2-
mediated degradation, substantiating that functional, full-length
USP7 is required for this protection (Figure 2B). In previous
studies, we observed that MDM2-mediated SUV39H1 loss
correlated with global reduction of the H3K9me3 mark (Munga-
muri et al., 2012). In good agreement, USP7-mediated protec-
tion of SUV39H1 from MDM2-mediated degradation rescued
H3K9me3 levels in the same cells, under the same conditions
(Figures 2A, 2B, and S2A).
Overexpressed SUV39H1 displayed constitutive ubiquitina-
tion, which was enhanced by exogenous MDM2 expression
(Figure 2C), whereas exogenous USP7 expression decreased
this ubiquitination in a dose-dependent manner (Figure 2C).
Collectively, these findings argue strongly that USP7 protects
SUV39H1 from MDM2-mediated degradation.
USP7 Forms a Trimeric Protein Complex with SUV39H1
and MDM2
USP7 has been shown to protect both MDM2 from auto-ubiqui-
tination and p53 from MDM2-mediated ubiquitination via phys-
ical interactions (Cummins et al., 2004; Li et al., 2002; Sheng
et al., 2006). Thus, we tested the nature of the interactions, if
any, among USP7, SUV39H1, and MDM2. Immunoprecipitation
followed by immunoblot analysis of endogenous proteins using
USP7, SUV39H1, or MDM2 antibody in HCT116 WT cells re-
sulted in pull-down of the other two endogenous proteins,
implying the presence of a tri-molecular protein complex in
unstressed cells (Figure 2D). Further, this tri-molecular complex
was equally detectable in cell lysates treated with ethidium
bromide (Figure 2E). Whether or not the chromatin landscape,
specifically the p53 RE (response element), is required for forma-
tion of this tri-molecular complex, these findings suggest that its
stability is independent of DNA.
To further understand the role of USP7 catalytic activity
and protein domains required for its interaction with SUV39H1,
we used various tagged USP7 constructs. Co-expression of
FLAG-tagged USP7 WT and SUV39H1, followed by FLAG-
antibody pull-down and immunoblot analysis, established that
USP7 forms an easily detectable protein complex with SUV39H1
(Figure S3A). Furthermore, a myc-tagged USP7-C223S mutant
was also able to pull down SUV39H1 to a similar extent as
myc-tagged USP7 WT (Figure S3B). These results indicated
that USP7-SUV39H1 complex formation was independent of
USP7 catalytic activity. Next, we asked which domains of USP7
mediate this interaction by co-immunoprecipitation experiments
usingmyc-taggedconstructsexpressingdifferentUSP7domains.
While the USP7-NTD was able to pull down SUV39H1 to a similar
extent as full-length USP7, the USP7-CTD showed no detectable
interaction (Figure S3B), indicating that theNTDof USP7 is essen-
tial for protein complex formation with SUV39H1.
Previous studies have shown that MDM2 physically interacts
with USP7 (Sheng et al., 2006) and also forms a complex with
SUV39H1 (Fa˚hraeus and Olivares-Illana, 2014). We observed
a trimolecular protein complex among endogenous USP7,
SUV39H1, and MDM2 (Figures 2D and 2E). To assess whethers
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Figure 2. USP7 Interacts with SUV39H1 through MDM2 and Protects SUV39H1 from MDM2-Mediated Degradation
(A) Western blot analysis of H1299 cells transfected with SUV39H1, MDM2 and 1, 2, 3, or 4 mg FLAG-USP7 for 24 hr.
(B) Western blot analysis of H1299 cells transfected with SUV39H1, MDM2 and myc-tagged USP7 WT, C223S, NTD, or CTD expression constructs for 24 hr.
(C) Western blot analysis of SUV39H1 immunoprecipitated samples. H1299 cells were transfected with the indicated plasmids and 24 hr later SUV39H1 protein
was immunoprecipitated and loaded on a gradient SDS-PAGEgel and probedwith an anti-ubiquitin antibody. 8%of the sample used for immunoprecipitation (IP)
was also loaded and showed as the input.
(D) Western blot analysis of immunoprecipitates from HCT116 p53 WT cell lysates. 2% of the sample used for IP was also loaded and showed as the input.
(E) Western blot analysis of immunoprecipitates from HCT116 p53 WT cell lysates. The cell lysates for treated with EtBr to denature the DNA, before performing
immunoprecipitation. 2% of the sample used for IP was also loaded and showed as the input.
See also Figure S3.USP7-SUV39H1 complex formation was dependent on MDM2,
we performed USP7 immunoprecipitation in the absence
and presence ofMDM2 silencing (Figure S3C). USP7was unable
to form a protein complex with SUV39H1 in MDM2 pre-silencedCellcells (Figure S3D). Moreover, MDM2 silencing in p53/ cells did
not increase SUV39H1 steady-state levels, arguing that USP7
stabilization of SUV39H1 occurred only in the presence of
MDM2 (Figure S3E). Further, overexpression of USP7 enhancedReports 14, 2528–2537, March 22, 2016 ª2016 The Authors 2531
the endogenous study-state levels of SUV39H1 only in control
cells, but not in the cells in which MDM2 was pre-silenced (Fig-
ure S3F). Collectively, these results indicate that shared physical
interactions of USP7 and SUV39H1 with MDM2 are required
either for USP7 to deubiquitinate SUV39H1 or for MDM2 to ubiq-
uitinate SUV39H1, both resulting in enhanced SUV39H1 stability.
Further, our data that silencing MDM2 in p53-null cells does not
further stabilize SUV39H1 argue that silencing MDM2 not only
abrogated the degradation of SUV39H1 but also inhibited
SUV39H1 interaction with USP7 and thus as a net effect has
no change in SUV39H1 protein levels.
USP7Occupies p53 Target Promoters andMaintains the
H3K9me3 Mark
One possible mechanism for retention of SUV39H1/ H3K9me3
mark on p53 target promoters in unstressed p53 WT cells could
be that USP7 is also recruited at these sites and protects
SUV39H1 fromMDM2-mediated degradation. In fact, chromatin
immunoprecipitation (ChIP) analysis indicated that USP7 was
enriched on p53 target promoters in HCT116 (Figure S4A) and
B5/589 cells (Figure S4B), both harboring WT p53.
In response to nutlin3a treatment, we observed increased p53
occupancy on its target promoters (Figure S4C), associated with
a decrease in USP7 occupancy on these same p53 target pro-
moters (Figures S4A and S4B). To further validate these data,
we performed a time-course analysis (0, 1, 2, 3, and 4 hr) of nut-
lin3 treatment of p53WT cells to investigate how p53 enrichment
influences the presence of USP7 and the H3K9me3 mark on p53
target promoters. The results establish that as p53 promoter
occupancy increases with time of nutlin3 treatment, there is a
decrease in USP7 occupancy and H3K9me3 enrichment on
these same promoters (Figures S5B–S5D). Moreover, these re-
sults establish that the loss of USP7 occupancy and H3K9me3
enrichment on p21 and PUMA promoters precede detectable in-
creases in p53 promoter occupancy. All of these findings are
consistent with a model in which basal recruitment of MDM2
by p53 leads to basal recruitment of USP7-SUV39H1 and a basal
level of H3K9me3. Under these same conditions, we observed
no detectable changes in total cellular USP7 levels, as measured
at both mRNA (Figures S6A and S6B) and protein (Figures S6C
and 5A) levels.
We showed previously that the H3K9me3 repressive histone
mark is enriched on p53 target promoters (Mungamuri et al.,
2012, 2014). USP7 knockdown by shRNA reduced total cellular
USP7 levels (Figures 1A and 1B) as well as USP7 promoter occu-
pancy in p53 WT cells (Figure 3A). Pharmacological inhibition of
USP7 did not reduce the total cellular pool of USP7 either in p53
WT or in p53-null cells, as measured at both the mRNA (Fig-
ure S6D) and protein (Figure 3B) levels. In HCT116 p53 WT cells,
such inhibition stabilized p53 protein (Figure 3B), associatedwith
enhanced p53 promoter occupancy (data not shown) and trans-
activation of p53 target genes (Figures 3B and S6D), as well as
reduced USP7 occupancy on these same p53 target promoters
(Figure 3C). In contrast, in p53-null cells, HBX41108 treatment
did not induce p53 pro-apoptotic target gene expression (Fig-
ure S6D). These results, collectively argue that p53 stabiliza-
tion/promoter occupancy is required for removal of USP7 from
p53 target promoters.2532 Cell Reports 14, 2528–2537, March 22, 2016 ª2016 The AuthorBoth shRNA-mediated USP7 silencing and pharmacological
USP7 inhibition in HCT116 p53 WT cells led to global reduction
of H3K9me3 levels (Figures 1A and 3B) as well as abrogation
of H3K9me3 mark enrichment on each of the p53 target pro-
moters analyzed (Figures 3D and 3E). Further, the loss of USP7
occupancy on p53 target promoters correlated with the abro-
gation of the H3K9me3 mark on these same promoters in a
time-dependent manner (Figure S5D). These results argue that
functional USP7 is required to maintain SUV39H1-dependent
H3K9me3 enrichment on p53 target promoters.
Reduced USP7 Expression/Activity Enhances
Chemotherapy-Induced p53-Dependent Apoptosis
Next, we sought to determine the functional significance of
USP7-mediated stabilization of SUV39H1 on p53-dependent
cell fate decisions. Etoposide, a topoisomerase II inhibitor,
induced apoptosis in HCT116 p53WT cells in a dose-dependent
manner, as analyzed by propidium iodide staining (Figures 4A
and S7A). The same cells showed significantly increased
apoptosis when either USP7 was pharmacologically inhibited
by pre-treatment with HBX41108 (Figures 4A and S7A) or
when USP7 expression was inhibited using shRNA (Figure S8).
The increases in apoptosis observed at different levels of etopo-
side in combination with HBX41108 and with shUSP7 were
greater in each case than the sum of either HBX41108 / shUSP7
or etoposide treatment alone. Further, this enhanced apoptosis
correlated well with increased induction of p53 target genes as
measured at both protein (Figure 4B) and mRNA levels (Figures
4C and S7B). HBX41108 also cooperated with nutlin3a-stablized
p53 to transactivate its target genes (data not shown), which was
associated with enhanced p53 promoter occupancy (Figure 4D).
Further, we also analyzed the H3K9me3 enrichment on p53
target promoters in HCT116 p53 WT cells under these con-
ditions. The results show that while etoposide or HBX41108
treatment alone decreased H3K9me3 enrichment on p53 target
promoters, their combined treatment further downregulated
H3K9me3 enrichment on these same promoters (Figure 4E).
Thus, loss of USP7 function favors increased p53 promoter oc-
cupancy and dependent transcription of its target genes through
abrogation of the H3K9me3 mark.
Finally, we confirmed the enhanced p53 occupancy/transac-
tivation in response to USP7 inhibition was indeed due to abro-
gation of the H3K9me3 mark on its target promoters, using
HCT116 p53 WT cells stably overexpressing either SUV39H1
WT or SUV39H1-K87A. In contrast to vector stables, expres-
sion of p53 targets was inhibited in response to etoposide or
HBX41108-mediated stabilization of p53 in cells stably overex-
pressing SUV39H1 WT (Figure 4B). In SUV39H1-WT-overex-
pressing cells, etoposide and HBX41108, either as single agents
or in combination, induced p53 targets less efficiently compared
to vector stables and were associated with higher residual levels
of SUV39H1 (Figure 4B). In SUV39H1-K87A-overexpressing
cells, neither etoposide nor HBX41108 alone or in combination
was able to induce p53 target genes (Figure 4B). In good agree-
ment, we did not observe degradation of SUV39H1-K87A under
any of these conditions (Figure 4B), despite comparable levels of
p53 stabilization and MDM2 induction across all of the cells
analyzed (Figure 4B). All of these findings argue that decreaseds
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Figure 3. USP7 Occupies p53 Target Promoters and Maintains the H3K9me3 Mark on These Promoters
(A) ChIP analysis showingUSP7 occupancy on p53 target promoters in HCT116WT cells stably transducedwith inducible shGFP or shUSP7 (two sequences) and
cultured in the presence of doxycycline for 48 hr.
(B) Western blot analysis of HCT116 p53 WT and p53/ cells treated with 0, 2.5, 5, or 10 mM HBX41108 for 24 hr.
(C) ChIP analysis showing H3K9me3 enrichment on p53 target promoters in HCT116 p53 WT cells stably transduced with inducible shGFP or shUSP7 (two
sequences) and cultured in the presence of doxycycline for 48 hr.
(D and E) ChIP analysis showing USP7 occupancy (D) and H3K9me3 enrichment (E) in HCT116 p53 WT cells treated with 10 mM HBX41108 for 24 hr.
See also Figures S4–S6.USP7 expression/activity leads to abrogation of the H3K9me3
repressive histone mark on p53 target promoters, enhancing
p53-promoter occupancy, transactivation of its target genes,
and the pro-apoptotic response.
SUV39H1 is known to influence global gene expression
(Kondo et al., 2008; Peters et al., 2001), and we reported previ-
ously that p53 regulates the expression of growth hormone
receptor (GHR), myostatin (GDF8), scinderin (SCIN), and ets
homologous factor (EHF) through downregulation of SUV39H1,
even though these gene promoters lack p53 binding sites (Mun-
gamuri et al., 2012). Thus, we analyzed the expression of these
same genes in response to USP7 and MDM2 silencing. While
USP7 silencing induced the expression of GHR, GDF8, SCIN,
and EHF (Figure S9A), silencing MDM2 had no effect on theCellinduction of these genes (Figure S9B). All of these results
argue that USP7 regulates SUV39H1 steady-state protein levels
and that downregulation of USP7 mimics downregulation of
SUV39H1, leading to abrogation of the H3K9me3 mark and
transactivation of target promoters. Further studies will be
necessary to determine the global effects on gene expression
mediated by USP7 and specifically how many of these changes
can be attributed to itsmodulation of SUV39H1/H3K9me3 levels.
DISCUSSION
A number of studies have indicated that in unstressed WT
p53 harboring cells, p53 occupies target promoters yet remains
transcriptionally inactive (Espinosa et al., 2003; Jackson andReports 14, 2528–2537, March 22, 2016 ª2016 The Authors 2533
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Figure 4. Pharmacological Inhibition of USP7 or USP7 Pre-silencing Enhances Chemotherapy-Induced Apoptosis in a p53-Dependent
Manner
(A) Propidium iodide (PI) staining in HCT116 p53WT cells pre-treated with either DMSOor 2.5 mMHBX41108 for 24 hr followed by treatment with increasing doses
of etoposide for 48 hr. The percentage of cells showing less than a 2N content of DNA (apoptosis) in each condition is shown in the table (see Figure S7A for actual
fluorescence-activated cell sorting [FACS] graphs).
(B) Western blot analysis of HCT116 p53WT cells stably expressing SUV39H1WT or SUV39H1-K87A are pre-treated with either DMSO or 2.5 mMHBX41108 for
24 hr followed by treatment with 5 mM of etoposide for another 24 hr.
(legend continued on next page)
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Pereira-Smith, 2006; Kaeser and Iggo, 2002). An anti-repression
mechanism has been postulated in which MDM2 co-occupies
these promoters and represses p53-dependent transcription
(Kruse and Gu, 2009; Minsky and Oren, 2004). Cellular stresses,
which stabilize p53, result in MDM2 promoter clearance, thus
relieving MDM2 repression and allowing p53 to function. The
presence of the H3K9me3 histone repressive mark represents
another major obstacle to p53 transactivation in unstressed
cells. We recently established that the repressive chromatin
conformation associated with this mark inhibits p53-dependent
transcription of its target genes and that p53 overcomes such
repression through MDM2-mediated degradation of SUV39H1,
the writer of this mark (Mungamuri et al., 2012).
The MDM2 E3 ubiquitin ligase is both a p53 transcriptional
targetand inanegative feedback loop targetsp53 forproteasomal
degradation (Beckerman and Prives, 2010). The USP7 deubiquiti-
nase is known to modulate the p53 pathway by protecting p53
from MDM2-mediated degradation (Cummins et al., 2004) and
MDM2 from auto-ubiquitination (Li et al., 2004). Evidence that
USP7 is present in the chromatin fraction (Maertens et al., 2010)
and that MDM2 also degrades SUV39H1 led us to investigate
a possible role of USP7 in protecting SUV39H1 from MDM2-
mediated degradation. Our present studies establish that USP7
is enriched on p53 target promoters and modulates SUV39H1/
H3K9me3 levels inanMDM2-dependentmanner.Moreover, either
USP7 knockdown or a USP7 small-molecule inhibitor led to a
global decrease in SUV39H1 protein and H3K9me3 levels as well
as abrogation of the H3K9me3 mark on p53 pro-apoptotic target
promoters. Thus, our findings support the concept that USP7
through its interactionswith SUV39H1 andMDM2plays an impor-
tant role in enforcing MDM2-mediated repression of p53-depen-
dent transcription of its target genes in unstressed cells.
Previous reports have indicated that MDM2 binds USP7
through interactions mediated by MDM2 aa 147–159 (Sheng
et al., 2006), while aa 200–262 are involved in MDM2 binding to
SUV39H1 (Fa˚hraeus and Olivares-Illana, 2014). Our present
studies demonstrate that USP7, SUV39H1, and MDM2 exist
in a trimeric complex and that the USP7-MDM2-SUV39H1
complex keeps MDM2 inactive under basal conditions. These
findings are consistent with a model in which USP7 regulates
SUV39H1protein levels indirectly bymodulatingMDM2E3 ligase
activity. Alternatively,MDM2bindingof bothUSP7andSUV39H1
mayplace thesemolecules in close proximity such that low-affin-
ity interaction not detectable in the absence of MDM2 may allow
USP7 to directly deubiquitinate SUV39H1. By either mechanism,
our results establish that USP7 modulates the repressive
H3K9me3 mark by protecting SUV39H1 from MDM2-mediated
degradation and blocking aberrant p53 transactivation of target
genes in unstressedp53WTcells.Whether this protectionoccurs
onp53 target promoters alone and/or elsewherewithin the cell as
well as the physiological significance of these interactions in a
p53 null context remain to be elucidated.(C) Real-time qPCR analysis of HCT116 p53 WT cells stably transduced with in
doxycycline for 24 hr (instead of 48 hr, in order to minimize the extent of p53 activ
by treating cells with 10 mM nutlin3a for another 16 hr.
(D and E) ChIP analysis showing p53 occupancy (D) and H3K9me3 enrichment (E)
or 2.5 mM HBX41108 for 24 hr followed by treatment with 10 mM nutlin3a for ano
CellOur present findings aswell as data available fromprevious re-
ports indicate that ‘‘basal’’ levels of mostly transcriptionally inac-
tive p53 enable the recruitment of the USP7-MDM2-SUV39H1
complex to p53 REs via p53-MDM2 interaction, placing the
H3K9me3 repressive mark and maintaining low basal transcrip-
tion activity of p53 target genes (Figure 5). Upon p53 activation
by stress stimuli or nutlin3, p53-MDM2 interaction is disrupted,
leading to increased p53 accumulation and chromatin binding,
leading to productive transcription. MDM2 accumulation, as a
result of p53-dependent transcription, blocks SUV39H1-medi-
ated H3K9me3 enrichment and its repressive effect by triggering
SUV39H1 degradation. Thus, p53-dependent MDM2 accumula-
tion serves two purposes: (1) a negative feedback loop via p53
degradation once the stressful stimulus is relieved and (2) a
fast-forward loop whereas p53 transactivation is enhanced via
degradation of the SUV39H1.
Several studies have shown that USP7 directly affects
chromatin structure by deubiquitinating and stabilizing histone
H2A (Lecona et al., 2015) and histone acetyl transferase TIP60
(Gao et al., 2013), both of which enhance p53 function (Dar
et al., 2013; Shema et al., 2008). Our present findings demon-
strate that USP7 also has a major impact on p53 pro-apoptotic
signaling by altering H3K9me3 enrichment on p53 target pro-
moters, uncovering a new layer of p53 regulation at the chro-
matin level. We showed that inhibition of USP7 function through
shRNA-mediated knockdown or by pharmacological inhibition
cooperated with chemotherapy in inducing apoptosis in a p53-
dependent manner by favoring p53 promoter occupancy and
transactivation of its target genes. Such cooperation may be
clinically beneficial in allowing the use of lower levels of chemo-
therapy to achieve a better therapeutic index (Cheon and Baek,
2006; Nicholson and Suresh Kumar, 2011).EXPERIMENTAL PROCEDURES
Cell Lines, Plasmids, and Treatments
HCT116 p53 WT, HCT116 p53/, B5/589 (p53 WT), and H1299 (p53 null)
(Mungamuri et al., 2012; Mungamuri et al., 2014) cancer cells were used.
Specific gene silencing was achieved by using either pTripZ (Open Bio-
systems) or Tet-pLKO-puro (#21915; Addgene) vectors. Human SUV39H1
cDNA is previously described (Mungamuri et al., 2012). MDM2 and FLAG-
USP7 cDNA (Cummins et al., 2004; Zhou et al., 2001) were obtained from
Addgene (#16233 and #16655). Myc-USP7 WT and other deletion constructs
are described previously (Sarkari et al., 2010). Please see the Supplemental
Experimental Procedures for the list of chemicals and their concentrations
used in this study.
Real-Time qPCR and Western Blotting
RNA extraction and real-time qPCR was performed as described previously
(Mungamuri et al., 2012). Western blotting and flow cytometry were done as
described previously (Mungamuri et al., 2012). Please see the Supplemental
Information for the list of antibodies used in the study. All blots were developed
using the Odyssey fluorescence image scanner. Please see Table S1 for the
sequences of primers used.ducible shGFP or shUSP7 (two sequences) and cultured in the presence of
ation of its target genes and optimize the ability to detect cooperation) followed
on p53 target promoters in HCT116 p53WT cells pretreated with either DMSO
ther 16 hr. See also Figures S7–S9.
Reports 14, 2528–2537, March 22, 2016 ª2016 The Authors 2535
Figure 5. Schematic Diagram Illustrating the
Role of USP7 in Maintaining H3K9me3 Mark
on p53 Target Promoters
(I) In the absence of p53 induction, ‘‘basal’’ levels of
mostly transcriptionally inactive p53 enable the
recruitment of the MDM2-USP7-SUV39H1 com-
plex to p53 REs via the p53-MDM2 interaction,
placing the repressivemark H3K9me3 and keeping
basal transcription activity of the target genes low.
USP7 prevents both MDM2 auto-ubiquitination
and MDM2-mediated SUV39H1 degradation.
(II) With p53 induction, USP7 promoter occupancy
reduces, MDM2 accumulates in the cell, both
leading to degradation of SUV39H1 and loss of
H3K9me3 mark on p53 target promoters favoring
enhanced p53 promoter occupancy, subsequently
leading to H3K4me3 enrichment at the transcrip-
tion start site (Mungamuri et al., 2012, 2014).Immunoprecipitation Assay
For immunoprecipitation, cells were lysed in immunoprecipitation lysis
buffer and precleared with Protein A beads before immunoprecipitation.
Protein lysates were incubated with antibody overnight, and the antibody
complex was precipitated using Protein A beads. To analyze the role
of DNA in protein interactions, the immunoprecipitate was treated with
ethidium bromide.
ChIP Assay
ChIP experiments were performed as described previously (Mungamuri et al.,
2014). The target sequences were detected by quantitative real-time PCR
analysis of eluted DNA. The relative promoter occupancy over the input per-
centage is shown as a bar diagram. Acetylcholine receptor (AChR) was used
as a negative control. Please see Table S1 for the sequences of primers used.
Generation of Stable Cell Lines
HCT116 p53 WT, HCT116 p53/, and H1299 cells were infected with either
Tet-pLKO-shUSP7 or pTripZ: shMDM2 lentivirus and selected for puromycin
(2 mg/ml) resistance. Resistant clones were pooled to generate doxycycline-
inducible shRNA cell lines.
For further details, please refer to Supplemental Experimental Procedures.2536 Cell Reports 14, 2528–2537, March 22, 2016 ª2016 The AuthorSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
nine figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.049.
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